Protein Design Labs preclinical data

PDLI (Mountain View, Calif.) announced animal evidence that its bispecific antibodies have potential clinical use in preventing micrometastases after cancer therapy.

The bispecific antibody directed against the gp52 mouse mammary tumor viral protein, and the CD3e antigen on mouse T cells, prolonged survival and decreased lung tumor burden after intravenous injection of the tumor cells. ...